SURVIVAL OF THE IDIOPATHIC PULMONARY FIBROSIS (IPF) IN SPAIN. NATIONAL SEPAR REGISTRY

S. Jaimes Diaz (Valencia, Spain), J. Rodríguez Portal (Sevilla, Spain), E. Fernández Fabrellas (Valencia, Spain), M. Aburto Barrenetxea (Vizcaya, Spain), C. Valenzuela Valenzuela (Mdrid, Spain), L. Planas Cerezales (Barcelona, Spain), R. García Sevila (Alicante, Spain), E. Bollo De Miguel (León, Spain), S. Herrera Lara (Vslencia, Spain), J. González Ruiz (Salamanca, Spain), R. Sánchez Simón (Albacete, Spain)

Source: International Congress 2019 – Interstitial lung disease registries
Session: Interstitial lung disease registries
Session type: Thematic Poster
Number: 4724
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Jaimes Diaz (Valencia, Spain), J. Rodríguez Portal (Sevilla, Spain), E. Fernández Fabrellas (Valencia, Spain), M. Aburto Barrenetxea (Vizcaya, Spain), C. Valenzuela Valenzuela (Mdrid, Spain), L. Planas Cerezales (Barcelona, Spain), R. García Sevila (Alicante, Spain), E. Bollo De Miguel (León, Spain), S. Herrera Lara (Vslencia, Spain), J. González Ruiz (Salamanca, Spain), R. Sánchez Simón (Albacete, Spain). SURVIVAL OF THE IDIOPATHIC PULMONARY FIBROSIS (IPF) IN SPAIN. NATIONAL SEPAR REGISTRY. 4724

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
EVALUATION OF THE PALLIATIVE CRITERIA IN IDIOPATHIC PULMONARY FIBROSIS
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019


“ASSESSING THE TREATMENT EFFECT FROM MULTIPLE TRIALS IN IDIOPATHIC PULMONARY FIBROSIS.” L. RICHELDI. EUR RESPIR REV 2012; 21: 147–151.
Source: Eur Respir Rev 2012 21:263
Year: 2012


RELATIONSHIP BETWEEN AIR POLLUTION IN MADRID AND THE MORTALITY OF IDIOPATHIC PULMONARY FIBROSIS
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020


PREVALENCE AND CHARACTERISTICS OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS ADMITTED FOR PNEUMONIA ACQUIRED IN THE COMMUNITY.
Source: Virtual Congress 2020 – What is hot in idiopathic pulmonary fibrosis?
Year: 2020


PROGNOSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ACCORDING TO STRENGTH IN UPPER LIMBS
Source: International Congress 2019 – Lung function evaluation and prognosis of airway diseases
Year: 2019



IMPACT OF CHRONIC ANEMIA ON THE EVOLUTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION (COPDE)
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019


PULMONARY REHABILITATION AFTER LUNG TRANSPLANTATION: DEVELOPMENT OF A PROTOCOL
Source: International Congress 2019 – Lung transplantation: from bench to bedside
Year: 2019

PULMONARY HYPERTENSION IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS ON ANTI-FIBROTIC TREATMENT WITH PIRFENIDONE OR NINTEDANIB: CLINICAL EVALUATION AND PROGNOSTIC IMPACT
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021

EVOLUTION OF PATIENTS WITH BRONCHIOLITIS OBLITERANS SYNDROME (BOS) SECONDARY TO ALLOGENIC HAEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Source: International Congress 2019 – Clinical problems
Year: 2019


DIFFUSING CAPACITY (DLCO) AS A POTENTIAL SURROGATE MARKER FOR SCLERODERMA RELATED LUNG DISEASE– DATA FROM THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS
Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment
Year: 2017


GRANULOMATOUS-LYMPHOCYTIC INTERSTITIAL LUNG DISEASE (GLILD) IN CVID: A CASE-CONTROL SINGLE CENTER RETROSPECTIVE STUDY
Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues
Year: 2019

NON-CYSTIC FIBROSIS (CF) BRONCHIECTASIS: A 5-YEAR RETROSPECTIVE STUDY WITH A FOCUS ON PATIENTS WITH PRIMARY IMMUNODEFICIENCIES (PID)
Source: International Congress 2018 – Management of bronchiectasis and large airway diseases
Year: 2018


TEMPORAL RESOLUTION OF RIGHT VENTRICLE DYSFUNCTION IN PATIENTS WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM
Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism
Year: 2020


DIFFERENCES IN HOSPITAL COURSE IN COMMUNITY ACQUIRED PNEUMONIA (CAP) ACCORDING TO ANTIBIOTIC TREATMENT
Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia
Year: 2019

LUNG TRANSTHORACIC ULTRASOUND (TUS) ELASTOGRAPHY: USEFULNESS IN THE STUDY OF PLEURO-PULMONARY IMAGES SUSPECTED OF MALIGNANCY
Source: International Congress 2018 – Bronchoscopy and transthoracic ultrasound
Year: 2018

ANGIOTENSIN II BLOCKERS IN OBSTRUCTIVE PULMONARY DISEASE: A RANDOMISED CONTROLLED TRIAL.
Source: Eur Respir J 2006; 28: 1292
Year: 2006


CHARACTERIZATION AND SURVIVAL OF PATIENTS WITH SPINAL MUSCLE ATROPHY TYPE 1 ON HOME MECHANICAL VENTILATION PROGRAM OF MINISTRY OF HEALTH, CHILE
Source: International Congress 2017 – Latest insights into functional capacity, muscle weakness and physical activity in chronic lung diseases
Year: 2017


HEALTH RELATED QUALITY OF LIFE (HRQoL) AMONG PATIENTS WITH NON CYSTIC FIBROSIS BROCHIECTASIS (BE) IN STABLE PHASE
Source: International Congress 2018 – Management of bronchiectasis and large airway diseases
Year: 2018

HYPERCAPNIA AND FUNCTIONAL IMPROVEMENTS DURING PULMONARY REHABILITATION.
Source: Virtual Congress 2021 – Physical activity, exercise training and (tele)rehabilitation in respiratory patients
Year: 2021